These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36259235)

  • 1. Comparative cost savings of biosimilar and dose rounding utilization in oncology care.
    Abdelmeseh V; Brown BR; Huynh JP; Zullo AR
    J Oncol Pharm Pract; 2023 Sep; 29(6):1437-1442. PubMed ID: 36259235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential cost savings associated with dose rounding antineoplastic monoclonal agents.
    Francis SM; Heyliger A; Miyares MA; Viera M
    J Oncol Pharm Pract; 2015 Aug; 21(4):280-4. PubMed ID: 24821690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential cost savings by dose down-rounding of monoclonal antibodies in a community cancer center.
    Copur MS; Gnewuch C; Schriner M; Tharnish M; Gonen M; McDonald M; Kezeor J; Ramaekers RC; Gauchan D; Clark D; Greenwalt L; Mickey M; Norvell M
    J Oncol Pharm Pract; 2018 Mar; 24(2):116-120. PubMed ID: 29284380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia.
    Cesarec A; Likić R
    Appl Health Econ Health Policy; 2017 Apr; 15(2):277-286. PubMed ID: 27730538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
    Serna-Gallegos TR; La-Fargue CJ; Tewari KS
    Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost savings analysis and toxicity audit of a bevacizumab dose rounding policy at a community cancer center.
    Moore DC; McVey GN
    J Oncol Pharm Pract; 2018 Jan; 24(1):42-46. PubMed ID: 27760811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
    Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
    Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients.
    McBride A; Alrawashdh N; MacDonald K; Abraham I
    Future Oncol; 2022 Jan; 18(3):363-373. PubMed ID: 34747185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilar Use Among 38 ASCO PracticeNET Practices, 2019-2021.
    Bourbeau B; Lyman GH; Lei XJ; Jones L; Rosenthal J; Kozlik MM; Oettel KR; Tinger A; Page R
    JCO Oncol Pract; 2023 Jul; 19(7):516-522. PubMed ID: 37084324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Automated parenteral chemotherapy dose-banding to improve patient safety and decrease drug costs.
    Fahey OG; Koth SM; Bergsbaken JJ; Jones HA; Trapskin PJ
    J Oncol Pharm Pract; 2020 Mar; 26(2):345-350. PubMed ID: 31046608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and treatment characteristics of patients treated with the first therapeutic oncology biosimilars bevacizumab-awwb and trastuzumab-anns in the US.
    Jin R; Mahtani RL; Accortt N; Lawrence T; Sandschafer D; Loaiza-Bonilla A
    Ther Adv Med Oncol; 2021; 13():17588359211041961. PubMed ID: 35003333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Financial Impact of an Automated Oncology Dose-Rounding Initiative: One-Year Analysis.
    Dela-Pena JC; Eschenburg KA; LaRocca VW; Patel D; Hough SM
    JCO Clin Cancer Inform; 2021 Aug; 5():805-810. PubMed ID: 34351786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Biosimilar Use on Total Cost of Care and Provider Financial Performance in the Medicare Oncology Care Model: A Population-Based Simulation Study.
    Yang J; Chaudhry BI; Yue AT; Roth JA; Kelton JM; Shelbaya A; Tran L; Li M
    Adv Ther; 2024 Jan; 41(1):349-363. PubMed ID: 37957523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries.
    Lee SM; Jung JH; Suh D; Jung YS; Yoo SL; Kim DW; Kim JA; Suh DC
    BioDrugs; 2019 Aug; 33(4):423-436. PubMed ID: 31201616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.
    Abraham I; Han L; Sun D; MacDonald K; Aapro M
    Future Oncol; 2014; 10(9):1599-609. PubMed ID: 25145430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer.
    Hara F; Tajima K; Tanabe K
    Future Oncol; 2019 Apr; 15(12):1353-1361. PubMed ID: 30767568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of potential cost savings through chemotherapy and biotherapy dose-rounding at a pediatric institution.
    Graff JM; Cramer J; Kolb LL; Agherrabi Z; Burgess M
    J Oncol Pharm Pract; 2024 Jun; 30(4):705-709. PubMed ID: 37350075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer.
    Leung JH; Tai YS; Wang SY; Yip Fion HT; Tsung-Chin H; Chan AL
    Breast; 2022 Oct; 65():91-97. PubMed ID: 35870421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the dosing strategies of biologic agents and the theoretical impact of dose rounding.
    Lindsey S; Parsons LB; Figg LR; Rhodes J
    J Oncol Pharm Pract; 2018 Jan; 24(1):47-55. PubMed ID: 29251257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database.
    Kim J; Ha D; Song I; Park H; Lee SW; Lee EK; Shin JY
    Int J Rheum Dis; 2018 Jun; 21(6):1227-1236. PubMed ID: 29667324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.